Sandoz has announced that it received marketing authorization for the AirFluSal Forspiro salmeterol/fluticasone DPI for the treatment of asthma and COPD from Sweden and Hungary. The company’s version of Advair has also been approved by Denmark and Germany in the past month.
Sweden approved both the 50-500µg and 50-250µg dosage forms, while Hungary approved only the lower dosage.
Read the Sandoz press release on the Swedish approval.
Read the Sandoz press release on the Hungarian approval.
